C4 Therapeutics, Inc. (CCCC) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $3.48 (-4.64%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 26, 2026 | Etzer Darout | Barclays | $7.00 | +100.9% |
| Sep 23, 2025 | Derek Archila | Wells Fargo | $10.00 | +186.9% |
| Sep 22, 2025 | Etzer Darout | Barclays | $10.00 | +186.9% |
| Sep 15, 2025 | Sudan Loganathan | Stephens | $6.00 | +72.2% |
| Dec 19, 2024 | Derek Archila | Wells Fargo | $12.00 | +244.3% |
| Sep 19, 2024 | Etzer Darout | BMO Capital | $20.00 | +473.9% |
| Apr 11, 2022 | Chi Fong | Bank of America Securities | $15.00 | +330.4% |
Top Analysts Covering CCCC
CCCC vs Sector & Market
| Metric | CCCC | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | +105.9% | +16366.0% | +18.0% |
| P/E Ratio | -2.17 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $5M | $5M | $5M | 1 |
| 2026-12-31 | $5M | $5M | $5M | 2 |
| 2027-03-31 | $11M | $11M | $11M | 1 |
| 2027-06-30 | $11M | $11M | $11M | 2 |
| 2027-09-30 | $11M | $11M | $11M | 2 |
| 2027-12-31 | $11M | $11M | $11M | 1 |
| 2028-12-31 | $17M | $17M | $17M | 6 |
| 2029-12-31 | $601M | $601M | $601M | 5 |
| 2030-12-31 | $1.97B | $1.97B | $1.97B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.28 | $-0.28 | $-0.28 | 1 |
| 2026-12-31 | $-0.29 | $-0.29 | $-0.29 | 1 |
| 2027-03-31 | $-0.31 | $-0.31 | $-0.31 | 1 |
| 2027-06-30 | $-0.27 | $-0.27 | $-0.27 | 1 |
| 2027-09-30 | $-0.19 | $-0.19 | $-0.19 | 1 |
| 2027-12-31 | $-0.16 | $-0.16 | $-0.16 | 1 |
| 2028-12-31 | $-2.23 | $-1.30 | $-0.79 | 6 |
| 2029-12-31 | $0.22 | $0.22 | $0.22 | 4 |
| 2030-12-31 | $3.86 | $3.86 | $3.86 | 2 |
Frequently Asked Questions
What is the analyst consensus for CCCC?
The consensus among 3 analysts covering C4 Therapeutics, Inc. (CCCC) is Buy with an average price target of $7.00.
What is the highest price target for CCCC?
The highest price target for CCCC is $20.00, set by Etzer Darout at BMO Capital on 2024-09-19.
What is the lowest price target for CCCC?
The lowest price target for CCCC is $6.00, set by Sudan Loganathan at Stephens on 2025-09-15.
How many analysts cover CCCC?
3 analysts have issued ratings for C4 Therapeutics, Inc. in the past 12 months.
Is CCCC a buy or sell right now?
Based on 3 analyst ratings, CCCC has a consensus rating of Buy (2.00/5) with a +105.9% upside to the consensus target of $7.00.
What are the earnings estimates for CCCC?
Analysts estimate CCCC will report EPS of $-0.28 for the period ending 2026-09-30, with revenue estimated at $5M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.